Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer.
Kim CG, Hong MH, Kim KH, Seo IH, Ahn BC, Pyo KH, Synn CB, Yoon HI, Shim HS, Lee YI, Choi SJ, Lee YJ, Kim EJ, Kim Y, Kwak JE, Jung J, Park SH, Paik S, Shin EC, Kim HR. Kim CG, et al. Among authors: paik s. Eur J Cancer. 2021 Jan;143:113-126. doi: 10.1016/j.ejca.2020.10.028. Epub 2020 Dec 7. Eur J Cancer. 2021. PMID: 33302114
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: paik s. Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424851 Clinical Trial.
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Kim HR, Moon YW, Lee YC, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: paik s. Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056. Oncotarget. 2015. PMID: 26462025 Free PMC article. Clinical Trial.
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN, Choi JW, Shim HS, Kim J, Kim DJ, Lee CY, Hong MH, Park SY, Park AY, Shin EJ, Lee SY, Pyo KH, Yun MR, Choi HM, Lee SS, Kim SY, Lee H, Paik S, Cho BC, Lee JG, Kim HR. Kang HN, et al. Among authors: paik s. Lung Cancer. 2018 Oct;124:168-178. doi: 10.1016/j.lungcan.2018.08.008. Epub 2018 Aug 11. Lung Cancer. 2018. PMID: 30268457
Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.
Youn JI, Park SM, Park S, Kim G, Lee HJ, Son J, Hong MH, Ghaderpour A, Baik B, Islam J, Choi JW, Lee EY, Kim HR, Seo SU, Paik S, Yoon HI, Jung I, Xin CF, Jin HT, Cho BC, Seong SY, Ha SJ, Kim HR. Youn JI, et al. Among authors: paik s. Sci Rep. 2020 Jun 3;10(1):9050. doi: 10.1038/s41598-020-65666-x. Sci Rep. 2020. PMID: 32493990 Free PMC article.
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
Kim HR, Kang HN, Yun MR, Ju KY, Choi JW, Jung DM, Pyo KH, Hong MH, Ahn MJ, Sun JM, Kim HS, Kim J, Yoo J, Kim KR, Koh YW, Kim SH, Choi EC, Yoon SO, Shim HS, Paik S, Kim TM, Cho BC. Kim HR, et al. Among authors: paik s. Br J Cancer. 2020 Dec;123(12):1720-1729. doi: 10.1038/s41416-020-01074-2. Epub 2020 Sep 23. Br J Cancer. 2020. PMID: 32963347 Free PMC article. Clinical Trial.
1,436 results